Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance. by Cornaglia, G. et al.
Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 339
Dispatches
Over the past few years, the increased
frequency of infections caused by Streptococ-
cus pyogenes (group A streptococcus [GAS])
and their sequelae has been reported in
several parts of the world (1,2). Even though
these reports may reflect an enhanced
awareness of and interest in these possibly
life-threatening infections on the part of the
medical community  (3), in at least some
areas, an increase in severe infections over
time has been documented (4,5).
Meanwhile, the increased clinical use of
erythromycin and its derivatives, mostly in
upper respiratory tract infections, has been
related to an increased resistance of GAS to
this antibiotic. Even though fewer than 5% of
GAS isolates are reported as resistant to
macrolide, lincosamide, and streptogramin
(MLS) antibiotics (2,6), local exceptions have
been reported, and widespread GAS resis-
tance to erythromycin has so far been
reported in Australia (17.6%) (7), Finland
(20%) (8), the United Kingdom (22.8%) (9),
Japan (60%) (10), and Taiwan (percentage
not specified) (11).
Awareness of GAS resistance to erythro-
mycin seems limited. Clinical microbiology
laboratories rarely determine erythromycin
susceptibility on a routine basis, and only
recently have erythromycin breakpoints for
streptococci other than S. pneumoniae been
added in the latest National Committee for
Clinical Laboratory Standards (NCCLS)
document (12). Since the late 1980s,
appreciable incidences of macrolide resis-
tance in cases of pharyngotonsillitis and
scarlet fever have also been reported from
Italy (13-15).
Temporal trends in GAS resistance to
erythromycin and clindamycin were system-
atically appraised on the basis of data
collected over the last 3 years from 15
laboratories that participated in the Italian
Surveillance Group for Antimicrobial Resis-
tance (ISGAR). All the strains were isolated
from throat swabs collected from symptom-
atic patients (mostly school-age outpatients)
from 1993 through 1995. The number of
isolates tested per year and the percentage of
resistant ones are represented in the Figure.
GAS were identified by beta-hemolysis
production on sheep or horse blood agar
plates and by the presence of Lancefield
group A antigen tested by commercial latex
agglutination techniques (Streptex, Murex
Diagnostics Ltd., Dartford, England;
Phadebact, Boule Diagnostics AB, Huddinge,
Sweden). The susceptibility tests used either
the disk diffusion method (according to
NCCLS performance standards [16,17]) or
semiautomated microdilution tests (ATB,
bioMérieux S.A., Marcy-l’Etoile, France;
Sceptor, Becton Dickinson Diagnostic In-
strument Systems, Sparks, Maryland), which
were carried out as recommended by the
respective manufacturers. The disk diffusion
tests were read by manual measurement of
the inhibition diameters or by a semi-
automated system equipped with a video
camera and image processing software that
records the inhibition diameters (Bio-
Videobact, Biokit S.A., Barcelona, Spain).
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A survey of antibiotic resistance in Streptococcus pyogenes in Italy showed a
sharp increase in erythromycin resistance. In 1993, the incidence of erythromycin-
resistant strains was on average 5.1%, with marked variations by geographic area.
Two years later, the incidence of these strains had registered a 1.5- to roughly 20-fold
increase, with a mean value of 25.9%, exceeding 40% in three centers out of 13 and
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The data came from each automated reader
device through data acquisition interfaces
(created for that purpose by the respective
manufacturers) and were subsequently trans-
lated through the MyMic software package
(18) from individual proprietary formats into
a common file format (Xbase) and transmit-
ted to the reference center (Verona) on floppy
disks or by electronic mail.
Test results were originally attributed to
the different interpretive categories accord-
ing to the NCCLS documents in force up
untillate 1995 (16,17,19). After the data
arrived in the reference center, they were
reinterpreted on the basis of the new criteria
for testing streptococcal species in the latest
NCCLS document (12). The zone diameter
criteria for resistant and susceptible isolates
were  15 and  21, respectively, for erythro-
mycin, and  15 and  19, respectively, for clin-
damycin. The equivalent minimum inhibi-
tory concentration breakpoints (g/ml) for
resistant and susceptible isolates were  4 and
0.5, respectively, for erythromycin, and  1
and  0.25, respectively, for clindamycin.
The survey showed a dramatic increase
in the isolation of erythromycin-resistant
strains of GAS (Figure). Both the rapid
increase in the resistance rate in the areas
involved and the subsequent involvement of
other geographic sites caused considerable
immediate concern since erythromycin had
hitherto been effective against most isolates
of this species and had been the drug of
choice for treating streptococcal infections in
patients allergic to penicillin.
In 1993, the first year surveyed, the
incidence of erythromycin-resistant strains
was on average 5.1%, with marked variations
according to geographic area, from 0% (all 19
strains from Pistoia) to 19.1% (Sassari, 18
strains out of 94). Two years later, in 1995,
the incidence of resistant strains had
registered a 1.5- to roughly 20-fold increase,
with a mean value of 26.8%, from 13%
(Palermo area, 3 strains out of 23) to 62%
(Venice area, 31 strains out of 50). This
incidence again showed geographic varia-
tions, but exceeded 40% in three centers out
of 13 and 30% in another four. The Palermo
area yielded the lowest rate of resistant
strains, but its incidence of intermediate
strains was exceptionally high (39.1%, 9
strains out of 23, versus a 5% to 10% rate in
all other centers).
Resistance to clindamycin was more
difficult to evaluate since this antibiotic was
tested in only a few centers and on limited
numbers of isolates. An increase in
clindamycin resistance was recorded in five
out of the seven centers that made this kind
of data available. The highest rate of
clindamycin resistance in 1995 was recorded
in Verona (28.9%, 39 strains out of 135),
while the lowest was recorded in Sassari
(2.2%, one single strain out of 45). For all the
strains studied, normal levels of susceptibil-
ity to penicillin and ampicillin were re-
ported.
Molecular typing of erythromycin-resis-
tant isolates was performed on strains
isolated in the area of Verona in the first 2
months of 1995 (Table). Nine strains out of
14 were resistant to erythromycin, the 16-
membered macrolide miokamycin, and the
lincosamide clindamycin (the so-called MLS
B
phenotype, which has reduced binding of
MLS antibiotics to their shared 50S rRNA
target site [9,20]); the other five strains were
resistant to erythromycin but not to
miokamycin or clindamycin (the so-called M
phenotype, in which resistance is attributed
to an efflux system [21]). All strains of the
Figure. Number of GAS isolates tested per year
and percentage of resistance to erythromycin and
clindamycin, Italy, 1993-1995. Black bars repre-





















799Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 341
Dispatches
MLSB phenotype carried the ermAM gene,
which determines resistance to all MLSB
antibiotics, as investigated by polymerase
chain reaction (PCR) performed on total
DNA (22), by using the following oligonucle-
otide primers (sequence 5' to 3') derived from
the published sequence of the gene (23):
MLS1: AGAAACCGATACCGTTTACGA
MLS2: GGTCAATCGAGAATATCGTCA
The PCR studies used the control strain
Streptococcus sanguis V736, which carries
the ermAM gene in plasmid pVA736 (24). In
contrast, all strains of the M phenotype were
negative to the PCR analysis.
Five different DNA restriction profiles
(Table) were found by pulse-field gel
electrophoresis (PFGE) of genomic DNA
fragments digested with SmaI (Boehringer,
Mannheim, Germany), with C predominant.
Three profiles were found among MLSB
strains, and two among M strains; no profile
was common to both MLSB and M strains.
Serologic analysis with T-protein-spe-
cific antisera (Institute of Sera and Vaccines,
Prague, Czech Republic) showed seven T-
types. Within each PFGE type, similar but
not identical T-types were identified. Again,
no T-type was common to both MLSB and M
strains (Table).
Molecular typing results showed a great
heterogeneity of erythromycin-resistant iso-
Acknowledgments
We thank Becton Dickinson Italia S.p.A., biokit
Italia s.r.l., and bioMérieux Italia S.p.A. for interfacing
their instruments with the MyMic software; Andrea Di
Clemente and Maurizio Trombini for their excellent
technical assistance; and Anthony Steele for his help
with the English language version of this paper.  We
dedicate this article to Giuseppe Satta, long-time
promoter of the Italian Surveillance Group for
Antimicrobial Resistance, who died 9 October 1994 at
age 52.
Giuseppe Cornaglia,* Marco Ligozzi,*
Annarita Mazzariol,* Myriam Valentini,*
Graziella Orefici,† the Italian Surveillance
Group for Antimicrobial Resistance, ‡ and
Roberta Fontana*
*Institute of Microbiology, University of Verona,
Italy; †National Health Institute, Rome, Italy.
‡The Italian Surveillance Group for Antimicrobial
Resistance: Antonio Goglio, Cristiana Passerini Tosi,
Ospedali Riuniti di Bergamo; Massimo Gallina,
Panaiota Troupioti, Azienda Ospedaliera ‘Morelli’,
Bormio; Bruno Maranini, Riccardo Cioni, Ospedale
‘San Giuseppe’ Empoli; Pierluigi Nicoletti, Laura
Martelli, Azienda Ospedaliera ‘Careggi’, Florence,
Sergio Frugoni, Amelia Berlusconi, Pio Albergo
Trivulzio, Milan; Roberto Rescaldani, Simone
Bramati, Ospedale ‘San Gerardo’, Monza; Alfredo
Chiarini, Anna Giammanco, Dipartimento di Igiene e
Microbiologia, Università di Palermo; Roberto
Rossetti, Spedali Riuniti, Pistoia; Gianfranco Santini,
Annapaola Callegaro, Ospedale Civile, Pordenone;
Giovanni Fadda, Teresa Spanu, Istituto di
Microbiologia, Università Cattolica del Sacro Cuore,
Rome; Alessandro Maida, Elena Muresu, Bianca
Maria Are, Istituto di Igiene e Medicina Preventiva,
Università di Sassari; Piero Cappuccinelli, Silvana
Table. Antibiotic susceptibilities,* presence of the ermAM
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Strain ERY† MIO‡ CLI§ ermAM PFGE T-protein
 type  pattern
VR1 R S S - A 8, 25
VR2 R S S - A 8, 25
VR3 R S S - A 25
VR4 R S S - A 8, 25
V R 5 RRR+ B 2 ,  2 8
V R 6 RRR+ C 5 ,  1 2 ,  2 7
VR7 R S S - D 4
VR8 R R R + C 12, 27
V R 9 RRR+ E 5 ,  1 2 ,  2 7
V R 1 0RRR+ B 2
VR11 R R R + C 12, 27
V R 1 3RRR+ C 5 ,  1 2 ,  2 7
VR14 R R R + C 12, 27





lates in Verona: by combining
the PFGE-type and the sero-
type, at least eight different
clones could be identified.
The polyclonality of Verona
isolates and the largely differ-
ent rates of erythromycin- and
clindamycin-resistance in most
centers seem to confirm that the
M phenotype of resistance has
become fairly frequent (21,25).
The diffusion of GAS strains
resistant to erythromycin and
susceptible to miokamycin and
clindamycin implies that test-
ing of erythromycin alone is no
longer sufficient to assess the
susceptibility of GAS to all MLS
antibiotics, contrary to the
claims made by Leclerq and
Courvalin (26).Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 342
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